Oral Administration of Tualang and Manuka Honeys Modulates Breast Cancer Progression in Sprague-Dawley Rats Model
Table 8
The immunohistochemical expression of pro- and antiapoptotic proteins in tumours treated with TH and MH compared with the tumours of nontreated control.
Tumors
Groups
1 +ive control
2 (1.0 g/kg TH)
3 (2.0 g/kg MH)
Total number
40
23
30
Number of Caspase-9 positive tumors (% expression)
12 (30)
16 (69.56)
21 (70)
Number of Apaf-1 positive tumors (% expression)
15 (37.5)
15 (65.21)
19 (63.33)
Number of p53 positive tumors (% expression)
17 (42.5)
14 (60.86)
20 (66.66)
Number of FASLG positive tumors (% expression)
15 (37.5)
0
0
Number of FADD positive tumors (% expression)
13 (32.5)
0
0
Number of IFNGR1 positive tumors (% expression)
20 (50)
17 (73.91)
25 (83.33)
Number of TNF- positive tumors (% expression)
30 (75)
17 (73.91)
22 (73.33)
Number of COX-2 positive tumors (% expression)
26 (65)
11 (47.82)
13 (43.33)
Number of ESR1 positive tumors (% expression)
32 (80)
14 (60.86)
17 (56.66)
Number of Bcl-xL positive tumors (% expression)
31 (77.5)
11 (47.82)
13 (43.33)
Kruskal-Wallis test; statistically significant differences between the groups, . FASLG: fas ligand, FADD: fas-associated via death domain, IFNGR1: interferon gamma receptor 1, TNF-: tumour necrosis factor alpha, COX-2: cyclooxygenase-2, ESR1: estrogen receptor 1, Bcl-xL: B-cell lymphoma extra large, +ive control: group bearing breast cancer but received no treatment, TH: Tualang honey, and MH: Manuka honey.
